New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - docetaxel 40 mg/ml;   - injection with diluent - 40 mg/ml - active: docetaxel 40 mg/ml   excipient: citric acid nitrogen polysorbate 80 ethanol nitrogen water for injection - head and neck cancer docetaxel, in combination with cisplatin and fluorouracil is indicated in the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - docetaxel 40 mg/ml;   - injection with diluent - 40 mg/ml - active: docetaxel 40 mg/ml   excipient: citric acid nitrogen polysorbate 80 ethanol nitrogen water for injection - head and neck cancer docetaxel, in combination with cisplatin and fluorouracil is indicated in the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - docetaxel 40 mg/ml;   - injection with diluent - 40 mg/ml - active: docetaxel 40 mg/ml   excipient: citric acid nitrogen polysorbate 80 ethanol nitrogen water for injection - head and neck cancer docetaxel, in combination with cisplatin and fluorouracil is indicated in the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - docetaxel 40 mg/ml - concentrate for infusion - 40 mg/ml - active: docetaxel 40 mg/ml excipient: polysorbate 80 ethanol water for injection

United States - English - NLM (National Library of Medicine)

accord healthcare inc. - docetaxel anhydrous (unii: 699121phca) (docetaxel anhydrous - unii:699121phca) - docetaxel anhydrous 40 mg in 1 ml - docetaxel injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. docetaxel injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. docetaxel injection as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. docetaxel injection in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. docetaxel injection in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer. docetaxel injection in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced ga

Malta - English - Medicines Authority

strides arcolab international limited unit 4, metro centre, tolpits lane, watford, hertfordshire, wd 189 ss, united kingdom - docetaxel - concentrate and solvent for solution for infusion - docetaxel 40 mg - antineoplastic agents

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - docetaxel 40 mg/ml - concentrate for infusion - 40 mg/ml - active: docetaxel 40 mg/ml excipient: polysorbate 80 ethanol water for injection - metastatic breast cancer taxotere is indicated for the treatment of patients with locally advanced or metastatic breast cancer in whom previous chemotherapy has failed. taxotere in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - docetaxel 10 mg/ml - concentrate for infusion - 20 mg/2ml - active: docetaxel 10 mg/ml excipient: citric acid ethanol nitrogen polysorbate 80 - metastatic breast cancer docetaxel sandoz is indicated for the treatment of patients with locally advanced or metastatic breast cancer in whom previous chemotherapy has failed. docetaxel sandoz in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - docetaxel 10 mg/ml - concentrate for infusion - 80 mg/8ml - active: docetaxel 10 mg/ml excipient: citric acid ethanol nitrogen polysorbate 80 - metastatic breast cancer docetaxel sandoz is indicated for the treatment of patients with locally advanced or metastatic breast cancer in whom previous chemotherapy has failed. docetaxel sandoz in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

wockhardt bio pty ltd - docetaxel, quantity: 160 mg - injection, concentrated - excipient ingredients: ethanol absolute; polysorbate 80; citric acid monohydrate - docetaxel concentrate for solution for infusion is indicated for;,breast cancer -,metastatic breast cancer : docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer in whom previous chemotherapy has failed. ,docetaxel in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy. ,docetaxel in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress her2 and who previously have not received chemotherapy for metastatic disease. ,adjuvant treatment of breast cancer : docetaxel in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with node-positive breast cancer. ,doxorubicin and cyclophosphamide followed by docetaxel in combination with trastuzumab (ac-th) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress her2. ,docetaxel in combination with carboplatin and trastuzumab (tch) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress her2. ,docetaxel in combination with cyclophosphamide is indicated for the adjuvant treatment of operable breast cancer with a primary tumour of ? 1cm and < 7cm. ,non small cell lung cancer -,docetaxel is indicated for the treatment of patients with locally advanced or metastatic non small cell lung cancer, including those who have failed platinum-based chemotherapy. ,ovarian cancer - docetaxel is indicated for the treatment of metastatic carcinoma of the ovary after failure of first-line or subsequent chemotherapy. ,prostate cancer -,docetaxel is indicated for the treatment of patients with androgen independent (hormone refractory) prostate cancer. ,head and neck cancer -,docetaxel, in combination with cisplatin and fluorouracil is indicated as induction treatment prior to chemoradiotherapy, for the treatment of patients with locally advanced, squamous cell carcinoma of the head and neck, who have low probability of surgical cure, require organ preservation or where the tumour is technically unresectable.